All In Biotech

Drug Trial Radar · NCT02842086

Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex With Men and Are At Risk of HIV-1 Infection

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 5,399 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

5,399

Actual

Start

Sep 2, 2016

Primary completion

Jan 31, 2019

Study completion Jul 29, 2026

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Jul 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of this study is to assess the rates of HIV-1 infection in Men (MSM) and transgender women (TGW) who have sex with men and who are administered daily emtricitabine/tenofovir alafenamide (F/TAF) or emtricitabine/tenofovir disoproxil fumarate (F/TDF) with a minimum follow-up of 48 weeks and at least 50% of participants have 96 weeks of follow-up after randomization.

Conditions

  • Pre-Exposure Prophylaxis of HIV-1 Infection

Interventions

  • F/TAFDrug

    200/25 mg tablet administered orally once daily

  • F/TDFDrug

    200/300 mg tablet administered orally once daily

  • F/TAF PlaceboDrug

    Tablet administered orally once daily

  • F/TDF PlaceboDrug

    Tablet administered orally once daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of HIV-1 Infection Per 100 Person Years (PY)Time frame: When all participants completed minimum follow-up of 48 weeks and at least 50% of the participants completed 96 weeks of follow-up after randomization or permanently discontinued from the study (maximum 125 weeks)

Locations

93 sites in 11 countries. Site status is shown where the registry gives one.

  • Site not named

    Beverly Hills, California

  • Site not named

    Los Angeles, California

  • Site not named

    Los Angeles, California

  • Site not named

    Newport Beach, California

  • Site not named

    Oakland, California

  • Site not named

    Sacramento, California

  • Site not named

    Sacramento, California

  • Site not named

    San Diego, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    San Francisco, California

  • Site not named

    Torrance, California

  • Site not named

    Aurora, Colorado

  • Site not named

    Denver, Colorado

  • Site not named

    New Haven, Connecticut

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Washington D.C., District of Columbia

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Fort Lauderdale, Florida

  • Site not named

    Ft. Pierce, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Orlando, Florida

  • Site not named

    Pensacola, Florida

  • Site not named

    West Palm Beach, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Macon, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    New Orleans, Louisiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Springfield, Massachusetts

  • Site not named

    Berkley, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Minneapolis, Minnesota

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Somers Point, New Jersey

  • Site not named

    Santa Fe, New Mexico

  • Site not named

    New York, New York

Showing 40 of 93 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.